Technical Analysis for ICPT - Intercept Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 77.77 -0.75% -0.59
ICPT closed down 0.75 percent on Wednesday, June 26, 2019, on 47 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
2 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ICPT trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
New 52 Week Closing Low Bearish 0.00%
NR7 Range Contraction 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
New 52 Week Closing Low Bearish -0.75%
Multiple of Ten Bearish Other -0.75%
Down 3 Days in a Row Weakness -0.75%
Down 4 Days in a Row Weakness -0.75%

Older signals for ICPT ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
Basic chart:
Profile
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog and farnesoid X receptor (FXR) agonist that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trials to treat portal hypertension; in Phase IIb clinical trials for the nonalcoholic steatohepatitis treatment; and in Phase IIa trials for the treatment of bile acid diarrhea. The company is also developing INT-767, an orally administered FXR and TGR5 agonist, which is in preclinical studies to treat fibrosis; and INT-777, an orally administered TGR5 agonist that has completed preclinical studies for the treatment of type 2 diabetes. It has strategic collaborations and research agreements with Dainippon Sumitomo Pharma Co. Ltd. and TES Pharma Srl. The company was founded in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals, Inc. is a subsidiary of Genextra S.p.A.
Medical Specialties Diabetes Gastroenterology Hepatology Digestive Diseases Fibrosis Obeticholic Acid Primary Biliary Cholangitis
Is ICPT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jun 25 Stifel likes Viking Therapeutics in premarket analyst action
Jun 21 Intercept: Amid The FDA Draft Guidance, OCA Will Be Approved
Jun 21 An Intrinsic Calculation For Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Suggests It's 43% Undervalued
Jun 17 ContraVir Moves Higher After NASH Drug Shows 100% Efficacy In Fibrosis Prevention
Jun 14 Intercept Pharmaceuticals, CymaBay’s and Viking’s Competitor
Jun 14 Is Intercept Pharmaceuticals Inc (ICPT) A Good Stock To Buy?
Jun 13 Intercept up 4% from intraday low as RBC defends
Jun 12 CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study
Jun 11 CymaBay Therapeutics stock down 43% after NASH trial data disappoint investors
Jun 7 Why Is Intercept (ICPT) Down 5.2% Since Last Earnings Report?
See more ICPT news...
Indicators
Indicator Value
52 Week High 133.74
52 Week Low 73.01
Average Volume 703,996
200-Day Moving Average 102.3208
50-Day Moving Average 85.098
20-Day Moving Average 81.4675
10-Day Moving Average 81.109
Average True Range 3.215
ADX 23.58
+DI 16.87
-DI 27.4254
Chandelier Exit (Long, 3 ATRs ) 78.325
Chandelier Exit (Short, 3 ATRs ) 82.65500000000001
Upper Bollinger Band 85.7763
Lower Bollinger Band 77.1587
Percent B (%b) 0.07
BandWidth 10.577961
MACD Line -2.015
MACD Signal Line -2.0114
MACD Histogram -0.0036
Fundamentals Value
Market Cap 1.95 Billion
Num Shares 25.1 Million
EPS -15.49
Price-to-Earnings (P/E) Ratio -5.02
Price-to-Sales 20.99
Price-to-Book 8.77
PEG Ratio -0.61
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 80.59
Resistance 3 (R3) 80.82 80.11 80.12
Resistance 2 (R2) 80.11 79.39 80.00 79.96
Resistance 1 (R1) 78.94 78.95 78.59 78.71 79.81
Pivot Point 78.23 78.23 78.05 78.12 78.23
Support 1 (S1) 77.06 77.51 76.71 76.83 75.73
Support 2 (S2) 76.35 77.07 76.24 75.58
Support 3 (S3) 75.18 76.35 75.42
Support 4 (S4) 74.95